

Diosgenin blocks neuroinflammation in LPS-activated BV2 microglia through mechanisms involving NF- κ B

Neuroinflammation is the first line of defence of the central nervous system (CNS) against harmful substances. The pathological mechanisms of neuroinflammation are caused by complex pathological processes including microglial activation (1). Diosgenin is a plant-derived steroidal saponin found in fenugreek (*Trigonella foenum-graecum*), and roots of wild yam (*Dioscorea villosa*) (2). Some studies have suggested that diosgenin induced anti-inflammatory activity against lipopolysaccharide (LPS)-induced inflammation in mouse primary peritoneal macrophage (3) and mouse lung injury (4). Our previous results showed that diosgenin has an anti-neuroinflammatory effect in LPS-stimulated BV2 cells (5). However, the mechanism of this effect has not yet been determined. In this study the anti-neuroinflammatory effects of diosgenin on LPS-induced nuclear factor kappa beta (NF- κ B) and p38 activation were investigated. BV2 cells were pre-incubated with diosgenin (5, 10, and 20 μ M) prior to stimulation with LPS (100 ng/ml). The effects of diosgenin on the main components of NF- κ B signalling pathway were evaluated using western blotting analysis, EMSA and luciferase reporter assay. In addition, protein expression of phospho-p38 was also determined. Diosgenin significantly ($p < 0.001$) decreased the phosphorylation of inhibitory kappa B α (I κ B- α) and the subsequent nuclear translocation of NF- κ B in LPS-activated BV2 cells. Pretreatment of BV2 cells with diosgenin at a concentration of 20 μ M resulted in 34.8 ± 8.5 phospho-I κ B- α and 30.8 ± 5.1 phospho-NF- κ B p65 protein expression when compared to LPS control. In addition, diosgenin significantly ($p < 0.01$) inhibited TNF- α -induced transcriptional activity of NF- κ B in HEK293 cells. At 20 μ M, diosgenin decreased the TNF- α -induced transcriptional activity of NF- κ B by 40.0 ± 6.6 when compared to the TNF- α control. Diosgenin reduced the LPS-induced DNA binding activity of NF- κ B in BV2 cells when compared to the LPS control. This compound did not inhibit the phosphorylation of p38 in LPS-stimulated BV2 cells. The results showed that diosgenin exhibits anti-neuroinflammatory activity through interference with NF- κ B signalling pathway in LPS-activated BV2 cells. Taken together, these results suggest that diosgenin might be useful in neurodegenerative diseases that are mediated by microglial hyperactivation.

1. Glass, C.K. et al., Mechanisms underlying inflammation in neurodegeneration. *Cell*, 2010. **140**(6): p. 918-934.
2. Raju, J. and C.V. Rao, Diosgenin, a steroid saponin constituent of yams and fenugreek: emerging evidence for applications in medicine. *Bioactive Compounds in Phytomedicine*, 2012. **125**: p. 143.
3. Jung, D.H., et al. (2010). Diosgenin inhibits macrophage-derived inflammatory mediators through down regulation of CK2, JNK, NF- κ B and AP-1 activation. *International immunopharmacology*, 2010. **10** (9): p. 1047-1054.
4. Gao, M., et al., Diosgenin down-regulates NF- κ B p65/p50 and p38MAPK pathways and attenuates acute lung injury induced by lipopolysaccharide in mice. *International immunopharmacology*, 2013. **15** (2): p. 240-245.
5. Abudheir, A. and O. Olajide, Diosgenin, a phytoestrogen inhibited LPS-activated neuroinflammation in BV2 microglia. <http://www.pA2online.org/abstracts/Vol12Issue3abst155P.pdf>.